Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Cookson

Showing results (271-280 of 279) with videos related to

Pageof 28
Sort By:
You have reached the last page of results.This site can display upto 279 results.
Urologic Oncology|February 15, 2020
Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancerDavid D'Andrea, Peter C Black, Homayoun Zargar, et al.
World Journal of Urology|September 28, 2022
Multicenter evaluation of neoadjuvant and induction gemcitabine-carboplatin versus gemcitabine-cisplatin followed by radical cystectomy for muscle-invasive bladder cancerSarah M H Einerhand, Anna J Black, Homayoun Zargar, et al.
World Journal of Urology|June 9, 2018
Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomyN Vasdev, H Zargar, J P Noël, et al.
Urologic Oncology|November 3, 2019
The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomyAnna J Black, Homayoun Zargar, Kamran Zargar-Shoshtari, et al.
The Lancet. Oncology|November 30, 2020
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trialStephen A Boorjian, Mehrdad Alemozaffar, Badrinath R Konety, et al.
European Urology|September 27, 2014
Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancerHomayoun Zargar, Patrick N Espiritu, Adrian S Fairey, et al.
European Urology|December 22, 2021
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical TrialAnirban P Mitra, Vikram M Narayan, Sharada Mokkapati, et al.
HGG Advances|January 7, 2022
Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to TreatmentYu Jiang, Travis J Meyers, Adaeze A Emeka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2020
Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019Veda N Giri, Karen E Knudsen, William K Kelly, et al.
Pageof 28

Showing results (271-280 of 279) with videos related to

Sort By:
Pageof 28
You have reached the last page of results.This site can display upto 279 results.
Urologic Oncology|February 15, 2020
Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancerDavid D'Andrea, Peter C Black, Homayoun Zargar, et al.
World Journal of Urology|September 28, 2022
Multicenter evaluation of neoadjuvant and induction gemcitabine-carboplatin versus gemcitabine-cisplatin followed by radical cystectomy for muscle-invasive bladder cancerSarah M H Einerhand, Anna J Black, Homayoun Zargar, et al.
World Journal of Urology|June 9, 2018
Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomyN Vasdev, H Zargar, J P Noël, et al.
Urologic Oncology|November 3, 2019
The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomyAnna J Black, Homayoun Zargar, Kamran Zargar-Shoshtari, et al.
The Lancet. Oncology|November 30, 2020
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trialStephen A Boorjian, Mehrdad Alemozaffar, Badrinath R Konety, et al.
European Urology|September 27, 2014
Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancerHomayoun Zargar, Patrick N Espiritu, Adrian S Fairey, et al.
European Urology|December 22, 2021
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical TrialAnirban P Mitra, Vikram M Narayan, Sharada Mokkapati, et al.
HGG Advances|January 7, 2022
Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to TreatmentYu Jiang, Travis J Meyers, Adaeze A Emeka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2020
Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019Veda N Giri, Karen E Knudsen, William K Kelly, et al.
Pageof 28